Research location
Rehlingen-Siersburg
Germany
Advertisement
Research activity in Rehlingen-Siersburg
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 50 trials and 50 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Rehlingen-Siersburg
50 linked trials · page 1 of 1A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)NCT05646706 · 2023-01-04 · 1 site observation
COMPLETED
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy RangeNCT05564117 · 2022-10-11 · 1 site observation
COMPLETED
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)NCT05035095 · 2021-09-13 · 1 site observation
COMPLETED
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily InsulinNCT04770532 · 2021-03-05 · 1 site observation
COMPLETED
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04760626 · 2021-03-01 · 1 site observation
COMPLETED
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 DiabetesNCT04707469 · 2021-01-15 · 1 site observation
COMPLETED
A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326 · 2019-06-17 · 1 site observation
COMPLETED
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561 · 2019-05-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 DiabetesNCT03689374 · 2018-10-01 · 1 site observation
COMPLETED
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or ObesityNCT03552757 · 2018-06-04 · 1 site observation
COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic DrugsNCT03078478 · 2017-03-13 · 1 site observation
COMPLETED
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal InsulinNCT02963922 · 2017-02-06 · 1 site observation
COMPLETED
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 DiabetesNCT02692716 · 2017-01-17 · 1 site observation
COMPLETED
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 DiabetesNCT02825251 · 2016-07-06 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.NCT02648204 · 2016-01-06 · 1 site observation
COMPLETED
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating InsulinNCT02967224 · 2015-11-05 · 1 site observation
COMPLETED
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 DiabetesNCT02461589 · 2015-09-21 · 1 site observation
COMPLETED
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With SulphonylureaNCT02471404 · 2015-09-21 · 1 site observation
COMPLETED
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)NCT02414958 · 2015-06-30 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 DiabetesNCT02305381 · 2014-12-01 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 DiabetesNCT02128932 · 2014-08-04 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 DiabetesNCT01885208 · 2013-12-02 · 1 site observation
COMPLETED
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 DiabetesNCT01836523 · 2013-11-01 · 1 site observation
COMPLETED
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 DiabetesNCT01831765 · 2013-08-26 · 1 site observation
COMPLETED
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice DailyNCT01814137 · 2013-03-01 · 1 site observation
COMPLETED
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin TherapyNCT01649297 · 2012-10-01 · 1 site observation
COMPLETED
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin GlargineNCT01680341 · 2012-08-31 · 1 site observation
COMPLETED
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin TherapyNCT01618162 · 2012-08-29 · 1 site observation
COMPLETED
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 DiabetesNCT01513590 · 2012-01-16 · 1 site observation
COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic TherapyNCT01499095 · 2011-12-01 · 1 site observation
COMPLETED
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and MetforminNCT01388361 · 2011-09-01 · 1 site observation
COMPLETED
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 DiabetesNCT01336023 · 2011-05-23 · 1 site observation
COMPLETED
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesNCT01289990 · 2011-02-01 · 1 site observation
COMPLETED
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 DiabetesNCT01232491 · 2010-10-29 · 1 site observation
COMPLETED
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPDNCT01285180 · 2010-08-01 · 1 site observation
COMPLETED
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 DiabetesNCT01159600 · 2010-07-01 · 1 site observation
COMPLETED
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsNCT01107886 · 2010-05-01 · 1 site observation
COMPLETED
Comparison of NN1250 With Insulin Glargine in Type 1 DiabetesNCT01079234 · 2010-03-01 · 1 site observation
COMPLETED
A Study on the Effect of 2 Pen Devices on HbA1cNCT00985712 · 2009-10-01 · 1 site observation
COMPLETED
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 DiabetesNCT00982644 · 2009-09-01 · 1 site observation
COMPLETED
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 DiabetesNCT00856986 · 2009-03-01 · 1 site observation
COMPLETED
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label ExtensionNCT00881530 · 2009-03-01 · 1 site observation
COMPLETED
BI 10773 add-on to Metformin in Patients With Type 2 DiabetesNCT00749190 · 2008-08-01 · 1 site observation
COMPLETED
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 DiabetesNCT00518882 · 2007-08-01 · 1 site observation
COMPLETED
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given TogetherNCT00318461 · 2006-05-01 · 1 site observation
COMPLETED
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 DiabetesNCT00095082 · 2004-09-01 · 1 site observation
COMPLETED
Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 DiabetesNCT00605020 · 2003-12-02 · 1 site observation
COMPLETED
Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 DiabetesNCT00604656 · 2003-05-05 · 1 site observation
COMPLETED
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 DiabetesNCT00283751 · 2003-03-01 · 1 site observation
COMPLETED
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 DiabetesNCT00312104 · 2002-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.